Ionis Pharmaceuticals, Inc. research snapshot
IONS AI stock analysis currently reads Ionis Pharmaceuticals, Inc. as a commercial-stage RNA medicine company with an established antisense platform, rising independent product sales, partner royalties, and several late-stage catalysts, but also negative earnings, cash burn, and a fresh WAINUA ATTR-CM trial failure. At the July 12, 2026 data cutoff, IONS last closed at $58.25 on July 10, implying a calculated market capitalization of about $9.63 billion using 165.26 million shares. This IONS AI stock analysis uses scenario ranges, technical levels, and source-backed facts for information only. It is not investment advice.
Current price
$58.25
Market cap
$9.63 billion calculated from 165.26 million shares
AI score
53 / 100
Rating
RNA medicines platform with launch momentum, high event risk, and negative cash flow
Trend status
Short-term bearish after the CARDIO-TTRansform miss; long-term platform trend unconfirmed
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Ionis discovers and develops RNA-targeted medicines, with TRYNGOLZA and DAWNZERA sales, SPINRAZA and WAINUA royalties, and a partner-rich late-stage pipeline. | High |
| Moat | ASO chemistry, delivery know-how, disease biology, clinical experience, intellectual property, and a partner network form a real platform moat, but each product still needs clinical and commercial validation. | Medium-high |
| Management | Brett Monia's team is moving from partner-dependent royalties toward independent launches and a 2028 cash-flow breakeven goal; execution after the July trial miss is the key test. | Medium |
| Financial trend | FY2025 revenue rose 34% to $943.7 million and net loss narrowed to $381.4 million, but Q1 2026 still posted a $118 million operating loss and 2026 guidance implies another loss-making investment year. | High |
| Valuation | At $58.25, IONS is about 9.88x FY2025 revenue per weighted-average share, with negative earnings and negative free cash flow, so cheapness cannot be established using PE or FCF yield. | High |
| Technical trend | Daily technicals were Strong Sell after the July 9 gap down; RSI 11.34 is oversold while price sits below the 10-day, 20-day, and 50-day simple moving averages. | High |
| Risk level | Risk is high because of the WAINUA ATTR-CM failure, negative free cash flow, partner and revenue concentration, regulatory outcomes, and launch execution. | High |
| AI confidence | Confidence is high for reported facts and calculations, but lower for price outcomes because trial and regulatory events can overwhelm technical or valuation models. | High data confidence |
| Investment certainty | Ionis has platform and product evidence, but the current thesis requires proof of independent commercial growth and a credible path to cash-flow breakeven after a major clinical setback. | Low-medium |
IONS AI stock forecast
The IONS AI stock forecast is a medium-term scenario framework, not a price promise. Ionis is loss-making, so the audited three-scenario EPS command produces negative target prices when applied to FY2025 GAAP EPS of -$2.38; that output is not decision-useful. The ranges below are conditional market-re-rating bands anchored to $58.25, current launch guidance, cash-burn risk, and pipeline outcomes, not a fabricated intrinsic-value estimate.
$85 to $115
More likely if TRYNGOLZA reaches strong adoption in severe hypertriglyceridemia, Ionis improves 2026 revenue and operating-loss guidance, zilganersen and bepirovirsen receive positive regulatory outcomes, obudanersen advances, and the full WAINUA data set preserves a viable monotherapy or ATTRv-PN franchise.
$55 to $80
More likely if TRYNGOLZA and DAWNZERA ramp, SPINRAZA royalties remain durable, and part of the pipeline progresses, while WAINUA loses its ATTR-CM expansion option and Ionis remains loss-making through the next investment cycle.
$30 to $50
More likely if launch uptake, pricing, or reimbursement disappoint, zilganersen, bepirovirsen, or obudanersen slip or fail, WAINUA royalties weaken after the trial miss, and cash burn requires further financing or dilution.
IONS AI technical analysis
IONS AI technical analysis is bearish and oversold as of the July 10, 2026 close. Investing.com showed a daily Strong Sell signal, RSI of 11.337, MACD of -5.68, ATR of 2.6563, and price below the 10-day, 20-day, 50-day, and 100-day simple moving averages. The July 9 and July 10 selloff followed the official WAINUA trial update, so an oversold bounce would not by itself confirm a trend reversal.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $58.25 | Investing.com historical close for July 10, 2026, the latest completed trading session before the July 12 cutoff. |
| Immediate support | $58.20 to $58.25 | The July 10 intraday low was $58.20 and the close was $58.25. A decisive close below this area would leave the post-event breakdown without a tested short-term floor. |
| First resistance | $64.10 to $64.27 | The July 9 session low was $64.10 and the close was $64.27. This zone is the first reference for a stabilization attempt. |
| Next resistance | $70.35 | The July 9 session high was $70.35. A reclaim would improve short-term structure but would not repair the clinical thesis by itself. |
| Moving averages | 5-day $58.71; 10-day $60.54; 20-day $68.91; 50-day $76.80; 100-day $77.57 | Investing.com snapshot at July 10, 2026 showed price below every listed average except that the 5-day gap was narrow. The 200-day average was not included in that snapshot. |
| Momentum | RSI(14) 11.337; MACD(12,26,9) -5.68 | The RSI reading is deeply oversold and MACD is negative. Neither signal can distinguish a technical bounce from a new fundamental repricing. |
| Volume | 7.96 million shares on July 10; 20.45 million on July 9 | Volume expanded sharply during the two-day event-driven decline versus 2.28 million shares on July 8, confirming elevated participation and volatility. |
| Volatility | ATR(14) 2.6563; 52-week range $40.03 to $86.74 | The ATR and broad 52-week range indicate that position sizing and gap risk matter more than a single indicator. |
| Higher overhead supply | $83.92 to $86.74 | The July 8 daily range and 52-week high area form a substantial overhead reference after the July 9 trial-driven gap. |
| Invalidation | Close below $58.20; stabilization requires $64.27, then $70.35 | A close below the recent low weakens the oversold-bounce setup. Reclaiming the first resistance zones would be required before considering a technical recovery. |
IONS AI trading strategy
The IONS AI trading strategy is a rules-based framework for a clinical-event biotechnology stock, not personal advice. It should be used with live quotes, position sizing, SEC filings, the clinical calendar, regulatory updates, and explicit risk rules.
Wait for IONS to close back above $64.27 and then challenge $70.35 with confirming volume and no new negative clinical, regulatory, or product news. A later reclaim of the 20-day average near $68.91 would improve short-term confirmation, but the longer averages remain overhead.
A close below $58.20 invalidates the immediate recovery setup. Treat a gap below that level as event risk rather than as a routine pullback.
An RSI of 11.337 can support a tactical bounce toward $64.10 to $70.35 if the market receives no new negative information. Compare any bounce with volume, the WAINUA data review, TRYNGOLZA demand, and the next earnings release.
Do not treat oversold conditions as proof of a bottom. A new clinical or regulatory problem can push through support before a mean-reversion signal completes.
Track TRYNGOLZA severe hypertriglyceridemia sales and net price, DAWNZERA sales, WAINUA ATTRv-PN royalties and global sales, SPINRAZA royalties, 2026 revenue guidance, cash above $1.6 billion, the 2028 cash-flow breakeven goal, and each major readout or PDUFA date.
Reduce confidence if guidance falls, cash drops below the stated floor, financing or dilution increases, or pipeline outcomes fail to replace the lost ATTR-CM expansion opportunity.
Investment research summary
Ionis turns RNA target selection, antisense chemistry, delivery know-how, clinical evidence, regulatory work, and commercial partnerships into medicines and royalties. FY2025 commercial revenue was $435.8 million, while research and development revenue was $507.9 million, showing both the product engine and the lumpy deal engine.
The moat is strongest in accumulated ASO chemistry, disease biology, clinical development, intellectual property, regulatory experience, and partner access. It is not an automatic moat around every asset: competing modalities, safety, dosing, reimbursement, and clinical endpoints can still decide product success.
The thesis can fail through a second pipeline setback, weak TRYNGOLZA or DAWNZERA adoption, lower pricing, slower royalties, partner reprioritization, continued negative cash flow, or new financing and dilution. The July 2026 WAINUA ATTR-CM miss shows why a broad pipeline does not remove binary risk.
CEO Brett Monia and CFO Elizabeth Hougen are trying to shift Ionis toward independent launches while retaining large pharmaceutical partners. The 2025 refinancing and repayment of the 2026 convertible notes, the Recordati license for zilganersen outside the U.S., and the 2028 cash-flow breakeven goal show active capital and commercial planning, but sustained execution is still unproven.
RNA medicines and gene silencing are part of a long-term shift toward therapies that act on disease biology upstream of proteins. Ionis has commercial proof through SPINRAZA and newer launches, but the industry remains exposed to competing modalities, payer pressure, safety, manufacturing, regulatory standards, and clinical endpoint design.
At a calculated market capitalization of about $9.63 billion, IONS traded near 9.88x FY2025 revenue per weighted-average share while GAAP earnings and free cash flow were negative. The current margin of safety therefore depends on future launch revenue, partner royalties, pipeline approvals, and a credible path to cash-flow breakeven rather than on current earnings power.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| IONS latest completed-session price | $58.25 at the July 10, 2026 close | Investing.com historical data | July 12, 2026 |
| Market capitalization | $9.63 billion, calculated as $58.25 x 165.26 million shares; market cap verification variance 0.04% | StockAnalysis share snapshot and financial_rigor.py | July 12, 2026 |
| Shares outstanding reference | 165.26 million current share snapshot; FY2025 weighted-average shares were 160.01 million and year-end common shares were 163.305 million | StockAnalysis and Ionis 2025 Form 10-K | July 12, 2026 |
| FY2025 revenue trend | $943.711 million in 2025, versus $705.138 million in 2024 and $787.647 million in 2023 | Ionis 2025 Form 10-K and StockAnalysis | July 12, 2026 |
| FY2025 revenue mix | $435.848 million commercial revenue, including $115.3 million product sales and $285.5 million royalties; $507.863 million research and development revenue | Ionis 2025 Form 10-K | July 12, 2026 |
| FY2025 net loss and operating loss | GAAP net loss $381.387 million and loss from operations $381.7 million; Macrotrends cross-check was within 0.05% | Ionis 2025 Form 10-K, Macrotrends, and financial_rigor.py | July 12, 2026 |
| Cash and short-term investments | $2.677 billion at December 31, 2025 and about $1.9 billion at March 31, 2026 after the $633 million 2026 convertible-note maturity payment | Ionis 2025 Form 10-K and Q1 2026 earnings release | July 12, 2026 |
| Q1 2026 financial results | $246 million total revenue, $108 million commercial revenue, $138 million research and development revenue, and $118 million GAAP operating loss | Ionis Q1 2026 earnings release | July 12, 2026 |
| 2026 financial guidance | $875 million to $900 million total revenue, $425 million to $475 million non-GAAP operating loss, and more than $1.6 billion cash and short-term investments; TRYNGOLZA sales $100 million to $110 million and DAWNZERA sales $110 million to $120 million | Ionis Q1 2026 earnings release | July 12, 2026 |
| Commercial and pipeline catalysts | TRYNGOLZA was approved for severe hypertriglyceridemia on June 24, 2026; zilganersen has a September 22, 2026 PDUFA target; bepirovirsen has an October 26, 2026 PDUFA target; REVEAL key-cohort enrollment completed July 6, 2026 | FDA, Ionis press releases, and Ionis pipeline | July 12, 2026 |
| WAINUA CARDIO-TTRansform result | Phase 3 did not meet the primary composite endpoint; 1,432 participants were enrolled, 57% in each arm used a stabilizer at baseline, and a further 24% initiated one during the trial | AstraZeneca and Ionis trial update | July 12, 2026 |
| FY2025 free cash flow and valuation check | Approximate FCF of -$320.027 million, or -$1.96 per FY2025 share; PE and P/FCF are negative, while price to FY2025 revenue per weighted-average share is 9.88x | Ionis 2025 Form 10-K and financial_rigor.py | July 12, 2026 |
| Technical snapshot | Daily Strong Sell; RSI 11.337; MACD -5.68; ATR 2.6563; SMA5 $58.71, SMA10 $60.54, SMA20 $68.91, SMA50 $76.80, SMA100 $77.57 | Investing.com technical analysis | July 10, 2026 |
| Event-driven price and volume move | Close moved from $84.46 on July 8 to $64.27 on July 9 and $58.25 on July 10; volume was 2.28 million, 20.45 million, and 7.96 million shares respectively | Investing.com historical data | July 12, 2026 |
This IONS AI stock analysis page is an informational research tool only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are conditional scenarios based on available data as of July 12, 2026 and can be wrong if financial results, clinical data, regulation, competition, financing, or market sentiment change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
